arrow
K

Karen L. Smith

merck, rahway, new jersey, usa
H指数:33
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10

TroFuse-011研究设计:sacituzumab tirumotecan联合或不联合pembrolizumab治疗PD-L1 CPS<10的晚期三阴性乳腺癌

2026-07-310
OA
The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer

霍普金斯诊所的约翰霍普金斯希望: 支持转移性乳腺癌患者的综合需求

2025-01-270
PRE
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Neratinib和ado-曲妥珠单抗emtansine用于预处理和未治疗的人表皮生长因子受体2 (HER2) 阳性乳腺癌脑转移: 转化乳腺癌研究联盟试验022

2024-11-011
OAAI
Real-world activity of sacituzumab govitecan for metastatic breast cancer

Sacituzumab govitecan在转移性乳腺癌中的真实世界应用

2024-09-010
PRE
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
2024-05-020
PRE
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
CANCER
IF5.1
2024-01-180
PRE
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

乳腺癌后中断内分泌治疗以尝试怀孕

2023-05-0489
OA
Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+Breast Cancer Brain Metastases (BCBM)
2023-03-013
PRE
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)
2023-03-014
PRE
Phase II trial of palbociclib with fulvestrant in individuals with hormone receptorpositive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor
2023-03-010
PRE
Breast Cancer, Version 3.2022
2022-06-01491
OA
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation

通过患者报告的结果确定的治疗紧急症状与辅助内分泌治疗停药的关联

2022-04-2120
OA
Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy
2022-02-152
PRE